Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for lenograstim the scientific conclusions are as follows:

Based on the review of data on safety and efficacy by the Lead Member State and taking into account any comments provided by the PRAC, the PRAC considers that the risk-benefit balance of medicinal products containing the active substance lenograstim remains unchanged but recommends that the terms of the marketing authorisation(s) should be varied as follows:

Update of sections 4.4 and 4.8 of the SmPC to add venous and arterial thromboembolic events with the frequency unknown and update of section 4.8 to add C-reactive protein increased with the frequency unknown. The Package leaflet is updated accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for lenograstim the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing lenograstim is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing lenogrsastim are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.4
- **Venous and arterial thromboembolic events**

Cases of venous thromboembolism (such as deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (such as myocardial infarction and cerebrovascular event) have been reported in donors treated with lenograstim. Close monitoring is recommended in donors and patients with known risk factors for thrombosis (see section 4.8).

- Section 4.8

The following adverse reactions should be added under the SOC Investigations and SOC Vascular disorders, respectively: **C-reactive protein increased; Venous thromboembolism and**

Arterial thromboembolism.

Medra System Organ Class	Very common	Common	Uncommon	Rare	Very rare	Not known
Investigations						**C-reactive protein increased**
Vascular disorders						**Venous thromboembolism** **Arterial thromboembolism**

[…]

[…]

Package Leaflet

Section 2.

During the treatment with lenograstim, your doctor might recommend additional monitoring as some patients have developed blood clots in the veins and arteries (see also section 4 "Possible side effects")

[…]

Section 4.

Blood test results indicating inflammation (e.g. C - reactive protein increased).

Blood clots formation in veins and arteries.

[…]

Annex III

Timetable for the implementation of this position

]

Timetable for the implementation of this position

Adoption of CMDh position:	June 2020 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	10 August 2020
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	8 October 2020